Guosheng Yuan
Overview
Explore the profile of Guosheng Yuan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li R, Li W, Yang Q, Guan Y, Chen Y, Zhu P, et al.
Liver Int
. 2025 Mar;
45(4):e70066.
PMID: 40078069
Background And Aims: The impact of low-level viremia(LLV) on the efficacy of immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma(uHCC) patients remains unclear. This study aims to investigate the effect...
2.
Guan S, Yuan G, Bi G, Yu Q, Fang J, Chen J, et al.
J Sep Sci
. 2024 Dec;
47(23):e70042.
PMID: 39623559
Lenvatinib has been demonstrated effective in advanced hepatocellular carcinoma (HCC), but the pharmacokinetic-pharmacodynamics behavior of lenvatinib and its metabolites remains unclear. To investigate the pharmacokinetic-pharmacodynamics behavior of lenvatinib and its...
3.
Yuan G, Chen Y, Zhu P, Deng Q, Su K, Liu J, et al.
Heliyon
. 2024 Oct;
10(19):e37616.
PMID: 39398001
Background: Previous research has shown that combining tyrosine kinase inhibitors (TKIs) with immunotherapy results in synergistic clinical efficacy. Cadonilimab, the first approved bi-specific antibody targeting PD-1 and CTLA-4, was studied...
4.
Zhu W, Zhang Z, Chen J, Chen X, Huang L, Zhang X, et al.
Signal Transduct Target Ther
. 2024 Apr;
9(1):101.
PMID: 38643203
Strategies to improve T cell therapy efficacy in solid tumors such as hepatocellular carcinoma (HCC) are urgently needed. The common cytokine receptor γ chain (γ) family cytokines such as IL-2,...
5.
Yuan G, Li W, Zang M, Li R, Li Q, Hu X, et al.
Discov Oncol
. 2024 Mar;
15(1):68.
PMID: 38460053
Objectives: To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC)....
6.
Cheng X, Tang Y, He Q, Song J, Wang K, Li H, et al.
Aliment Pharmacol Ther
. 2023 Dec;
59(5):680-691.
PMID: 38155565
Background: Esophagogastroduodenoscopy (EGD) is required to screen for high-risk varices (HRV) in patients with hepatocellular carcinoma (HCC), especially since overall survival rates have dramatically improved with new systemic therapies. Aim:...
7.
Zang M, Hu X, Yuan G, Li R, Li W, Pang H, et al.
Int Immunopharmacol
. 2023 Oct;
125(Pt A):111019.
PMID: 37879230
Background: Hepatic arterial infusion chemotherapy (HAIC) has demonstrated promising benefits in treating advanced hepatocellular carcinoma (HCC). In China, the most frequently used HAIC regimen is oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX)....
8.
Fan W, Zhu B, Yue S, Zheng X, Yuan G, Yu L, et al.
Eur Radiol
. 2022 Dec;
33(4):2809-2820.
PMID: 36562786
Objective: To develop a prognostic model for post-transjugular intrahepatic portosystemic shunt (TIPS) patients with hepatocellular carcinoma (HCC) beyond the Milan criteria treated by transarterial chemoembolization (TACE). Design: Between January 2013...
9.
Hu X, Li R, Li Q, Zang M, Yuan G, Chen J
BMC Infect Dis
. 2022 Jul;
22(1):614.
PMID: 35836207
Background: A high baseline hepatitis B virus (HBV) load has always been listed as an exclusion criterion for programmed cell death-1 (PD-1) inhibitor-associated therapy in clinical trials, as the interaction...
10.
Fan W, Zhu B, Zheng X, Yue S, Lu M, Fan H, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(5):1873-1882.
PMID: 35788728
Purpose: To investigate the effectiveness and safety of the combination of sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in the treatment of early intrahepatic stage-progressed advanced hepatocellular carcinoma (ISPA-HCC). Methods:...